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Self-assembled nanoparticles as multifunctional
drugs for anti-microbial therapies†
Manpreet Bhatti,*a Timothy D. McHugh,b Lilia Milanesic and Salvador Tomas*a
A self-assembled nanoparticle containing a photosensitizer and a
Trojan-horse moiety (cholesterol), binds an anti-TB pro-drug and
increases 1000-fold its activity against mycobacteria. Theseminimalist
constructs will allow development of economically viable, eﬃcient
drug preparations for the treatment of drug-resistant TB infections.
The recent UK Chief Medical Oﬃcers report has emphasized the
increasing threat of antimicrobial resistance and the need for new
strategies for control.1,2 This is particularly true for tuberculosis
(TB). TB accounts for around 9 million new cases a year globally
and 1.4 million deaths.3 This fact is compounded by over half a
million cases of multi drug resistant (MDR) and extreme drug
resistant (XDR) TB per year. The options for treating TB are
limited, the drugs in the approved regimens were introduced in
the 1960’s and new moieties are still in early phase testing. The
cause for concern is that the new compounds are focused on
limited targets and so cross-resistance is a real risk.4 Clearly, new
paradigms for antimicrobial delivery are required. One such
paradigm may rest in the development of soft nanoparticles as
vehicles for targeted and controlled delivery.
In the last years the development of antimicrobials based on
nanoparticles has attracted strong interest.5,6 For the treatment
of Mycobacterium tuberculosis specifically, studies have so far
focused on the sustained drug delivery properties of relatively
simple nanoparticle preparations (mostly solid lipid and polymer
based), using traditional drugs.7,8 However nanoparticle assemblies
oﬀer the possibility of introducing functionality beyond the passive
release of the drug.9,10 The level of sophistication that can potentially
be reached is illustrated by the ‘‘artificial organelle’’ approach.11
These approaches, although potentially very eﬃcient, are expensive
to develop and produce. On the other hand, a nanoparticle can be
produced that is formed exclusively of small, uncomplicated mole-
cules, each one with diﬀerent functionality, but with an overall
therapeutic eﬀect that is larger than the sum of the individual parts.
Here we develop a multifunctional nanoparticle that can be poten-
tially applied to the treatment of TB. The nanoparticle will contain
bacterial nutrient, a photosensitizer (PS) for photodynamic therapy
(PDT) and an anti-TB drug. In PDT, a PS is activated by light of
an appropriate wavelength producing reactive oxygen species that
cause cell death. PDT is being used for cancer treatment,12 but its
application to bacterial infections has been so far limited.13,14
Recently, we described the synthesis and molecular recogni-
tion properties of very stable (CMC 11 nM), hydrophobically self-
assembled nanoparticles based on a Zn-metalloporphyrin amphiphile
that contained also cholesterol.15 We reasoned that nanoparticles
based on this design can be used for the targeted delivery of
drugs that bind to the nanoparticle. Additionally, the chemistry of
the amphiphile can be tailored in order to introduce targeting
and enhance transport and towards photodynamic therapy (PDT)
applications.16 For the development of an agent for the treatment of
mycobacterium infections, we used the same amphiphilic building
block as earlier described, but introduced Co instead of Zn as the
metal centre, leading to amphiphile 1 (Fig. 1 and ESI,† Fig. S1).
It is known that mycobacteria are capable of using cholesterol as
an important carbon source during infections and during growth in
culture.17 Therefore, the presence of the cholesterol in the molecule
is expected to provide some degree of targeting and facilitate the
transport inside the bacterium. Co was chosen as the porphyrin
metal centre for two reasons. First, Co metalloporphyrins are likely
to be more eﬃcient photosensitizers than Zn metalloporphyrins as
they quench oxygen at a slower rate than Zn metalloporphyrins,16
rendering a Co-porphyrin derivative a (potentially) better PDT agent.
Second, Co-metalloporphyrins have a stronger aﬃnity for N basic-
bearing ligands than the Zn counterparts, which will make it a more
eﬃcient molecular receptor to our drug model and potentially
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enhance its transport. A version of 1, unable to form nanoparticles,
1R, was also synthesized for comparison purposes (Fig. 1 and ESI,†
Fig. S2). As a drug model we synthesized a hydrophobic pyrazinoic
acid derivative, pyrazinoic acid hexylester 2, by treatment of
pyrazinoic acid with oxalyl chloride followed by addition of
hexanol (Fig. 1 and ESI,† Fig. S3)
While pyrazinoic acid is the active form of the drug,18 pyrazinoic
acid ester 2 was selected because its hydrophobicity should make it
bind more strongly to the nanoparticle than the free acid, and
because ester moieties hydrolyze slowly but spontaneously in water,
while amides typically require enzymatic assistance for the hydro-
lysis to take place in measurable timescales.19 This may lead to
bacterial resistance as demonstrated by mycobacterium resistance
to the prodrug pyrazinamide.20
Amphiphilic porphyrin 1 assembles into a nanoparticle of
similar size and appearance to that of the previously described
Zn derivative15 (Fig. 2A and B). The apparent binding aﬃnity of
pyrazinoic acid and the ester 2 with 1 was determined by means
of UV titration experiments (Fig. 2C and ESI,† Fig. S4). The binding
isotherm is consistent with the sequential binding of twomolecules
of 2 for each molecule of receptor 1. This result is in agreement
with literature data on complexation of Co metalloporphyrins with
amines, which show that the metal centre can bind two ligands.21
The apparent binding constants are 3.4  104 M1 and 4.5 
103 M1 for the first and second binding event respectively (see
Materials and methods section for details and ESI,† Table S1).
In contrast, the binding of 2 to a cobalt porphyrin receptor
that does not form nanoparticles show binding constants of
4.5  103 M1 for the first binding event and 50 M1 for the
second (see ESI,† Table S1). Moreover, for the nanoparticle, but
not for 1R, the ligand may also bind in a non-specific manner
(yielding complexes with stoichiometry larger than 1 : 2) via
insertion of the hydrophobic tail. The implications are that,
upon de-assembly of the particle (for example, as the cholesterol
moiety is metabolized into the bacteria), the drug will be more
easily released. TEM pictures of 1 show that the ligand increases
the size of the nanoparticles from an average 9.5 to 12.3 nm
diameter in presence of 2 (Fig. 2B and D), consistent with ligand
binding to the nanoparticle.
Mycobacterium fortuitum was chosen as a model for in vitro
bacteria killing experiments. M. fortuitum is a fast growing myco-
bacterium that can be manipulated under containment level 2
conditions making it a useful surrogate for M. tuberculosis.22
M. fortuitum was treated either with nanoparticle 1, ester 2 or
nanoparticle 1 in presence of 2, at a molar ratio 2 : 1 drug 2/receptor
1 (see ESI,† for details). For M. fortuitum treated with 2 alone, a
concentration up to 50 mM (8.6 mg mL1) is required for bacterial
cell death under the conditions used in this study. Below these
concentrations the drug does not show any eﬀect. For these experi-
ments, the addition of water soluble porphyrin 1R up to 280 mM did
not have any eﬀect on the cell survival. For nanoparticle 1 alone, the
bacterium survival is around 40–50% when the concentration of the
nanoparticle 35 mM, going up to 60% when the concentration is
further lowered to 17.5 mM (Fig. 3A and ESI,† Table S2).
Irradiation of the samples with light at 430 nm (the maximum
absorption of the nanoparticle) results on a decrease in survival of
10–15% in relation to not irradiated samples for all the concentra-
tions tested (Fig. 3A and ESI,† Table S2). This result is attributed
to the photosensitizer action of themetalloporphyrinmoiety within
the bacteria upon irradiation. When treated with nanoparticle 1 in
the presence of 2, quantitative killing takes place for samples
280 mM in 1 (with 370 mM of 2 bound to nanoparticle), while the
survival of bacterium increases in a typical dose-dependent fashion
as the concentrations tested decrease, up to 50% survival for
Fig. 1 Chemical structure of water soluble porphyrin 1R, amphiphilic
porphyrin 1 and pyrazinoic acid ester 2, together with their cartoon
representations.
Fig. 2 (A) Cartoon representation of the nanoparticle assembly and the
formation of the complex nanoparticle-ester 2. (B) TEM picture (negative
stain) of 1 nanoparticles in the working buﬀer. The scale bar represents
20 nm. (C) Variation of the extinction coeﬃcient of a solution of nano-
particles upon addition of ester 2 (empty circles). The fitting to a binding
model for the sequential binding of two 2 molecules per molecule of 1 is
shown as a line for changes at 428 nm (upper curve) and at 415 nm (lower
curve). See ESI,† Table S1 for Kapp values and ESI,† Fig. S4B for limiting
values of extinction coeﬃcients. (D) TEM picture (negative stain) of the
nanoparticles in presence of 2. The scale bar represents 20 nm.
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samples with 17.5 mM in 1 (with 9.5 mMof 2 bound to nanoparticle)
(Fig. 3B and ESI,† Table S3). Finally, when samples treated with 1 in
presence of 2 are also irradiated at 430 nm quantitative killing takes
place down to concentrations of 1 35 mM (with 26 mM of 2 bound
to nanoparticle), while a survival of 40% approx. is observed
when the concentration is further lowered to 17.5 mM in 1 (with
9.5 mM of 2 bound to nanoparticle). This result is consistent with
the nanoparticle facilitating the transport of the pyrazinoic acid
ester 2, together with the expected photosensitizer action of the
porphyrin moiety.
In summary, this work shows that the combination of a small
molecule based nanoparticle (1) with the appropriate derivative
of a known drug (2) results in quantitative bacterial killing for
M. fortuitum, a widely used model for M. tuberculosis down to
15 mg mL1 from 10 mg mL1 for the drug 2 in absence of the
nanoparticle (Fig. 3 and ESI,† Tables S2 and S3). The enhancing
of the drug activity in the presence of the nanoparticle is
attributed to the ability of the nanoparticle to facilitate the
transport of the drug into the bacteria and is supported by the
fact that the nanoparticle on its own leads to bacterial killing
upon irradiation. The transport activity can be attributed to
the presence of a cholesterol moiety. Cholesterol is used by
M. fortuitum as nutrient enabling the transport of the other
moieties associated to it, such as drug model 2 and the
covalently linked Co metalloporphyrin moiety. It is also possible
that the nanoparticle components de-assemble when in contact with
the bacterial cell wall and incorporate as individual molecules.
Irradiation may then lead to bacterial wall damage resulting in
enhanced drug absorption. Whatever the precise mechanism of
action, these kinds of nanoparticles are a strong candidate to be
developed into therapeutic agents for resilient strains of tuberculosis
that currently require drastic treatment, including pulmonary
surgery.23 A combined therapy based on the use of a system such
as the one described here will oﬀer a much more convenient
alternative, both from the patient and the economic point of
view. The use of UV to enhance drug activity will not be practical
in most patients. However, in those with MDR and XDR
TB, where treatment options are limited, use of an adapted
bronchoscope could provide targeted UV delivery to the site of
disease. The modular nature of the nanoparticles and the
relative simplicity of the building blocks should allow us to
develop related systems with diﬀerent properties. For example, a
version bearing ergosterol may target fungi24 and can be tested
against post-transplant fungal infections. The potential toxicity
of our porphyrin derivatives may be mitigated by developing a
nanoparticle version bearing more biocompatible (e.g. heme
derivative) moieties. The potential of these systems is currently
being analysed in our labs.
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Fig. 3 (A) Percentage survival of M. fortuitum 4 days after treatment with
pure 1. Red columns represent the survival for non-irradiated samples and
the blue columns the survival for samples that where irradiated 24 hours
after exposure to the nanoparticle (75 J cm2 energy dose). (B) Idem for
samples treated with 1 and 2.The ratio of concentrations [2] : [1] is 2 in all
samples. The concentration of 2 bound to the nanoparticle is shown in
parenthesis and has been calculated from the binding constants. See ESI,†
Tables S2 and S3 for numerical data. In all cases, the error bars represent
twice the standard deviation of three measurements.
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